RezGen5 Limited is committed to alternative secondary listing

Hamilton, Bermudainseln; 4. November 2013-Rezgen5 Limited, listed on the stock exchange in Bermuda under the symbol REZG5.BH company, announced today, that the company is actively seeking to viable alternatives for a secondary listing on a major stock exchanges worldwide. RezGen5 previously listed on the Berlin Stock Exchange. This listing has been discontinued, however,, after the primary dealers of the company withdrew from market making at several cross-listings.

Stuart Garret, Founder and CEO of RezGen5, said: "I am very confident, that we will soon find a suitable market for a secondary listing of our shares. We currently weigh different options, to meet the needs of our investors are best. "Mr. Garret added to: "We are improving our scientific model and continue to work tirelessly on the commercialization of our anti-aging molecule, to promote the business of the company. "

About RezGen5 Limited

RezGen5 Limited is a biopharmaceutical company with headquarters in Bermuda, which focuses on the discovery and development of proprietary, orally available, low molecular weight drugs is, the potential for the treatment of age-related diseases, including metabolic diseases such as type 2 diabetes, Have Alzheimer's and cardiovascular diseases. RezGen 5 improving the quality of life of people committed to, by enabling people, to do more, to feel better and live longer. The company's headquarters is in Devonshire in Bermuda. Additional company information including a copy of this press release and details of the latest products of the company, which are in the development, get on www.Rezgen5.com.

Cautionary Note Regarding Forward-Looking Statements

The company cautions investors that, that any such forward-looking statements or predictions, taken by the company, including those in this release, Subject to risks and uncertainties, which could cause, the actual results to differ materially from the results predicted. Factors, that could affect the operating activities of the company, are available on the Company's website under the heading "Risk Factors" in the "Business Review" section.

This press release does not constitute an offer to sell or a solicitation to buy or sell the equities of RezGen5 Limited.

Investors and security holders are urged, to read each of these documents, as they become available.

Investors and shareholders may request it by contacting the Investor Relations department of RezGen5 Limited free copies of these documents beyond.

Contact: info@Rezgen5.com

For the correctness of the translation is any liability assumed! Please note original English message!

Which filings can be found at:
http://www.irw-press.at/press_html.aspx?messageID=29197

This entry was posted in News, News of the corporations, the rare earth metals and and tagged , , , . Bookmark the permalink.

Comments are closed.